Cannabinoid series: growing and extracting APIs
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
List view / Grid view
Michael Sassano from Somai Pharmaceuticals and Solaris Farms discusses the US and European markets for growing and extracting cannabinoids for the pharmaceutical industry.
Earlier this year, MGC Pharmaceuticals, in collaboration with the Slovenian National Institute of Biology (NIB) and the Neurosurgery Department at the University Medical Centre in Ljubljana, Slovenia, announced successful research results for their novel cannabinoid formulation, which has been developed for the treatment of glioblastoma. This article highlights the key…
According to research, the rise in demand for high-quality cannabis will also drive growth in the cannabis testing market, where new technologies are needed to overcome current limitations.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this third piece, we discuss the future of the cannabinoid industry and how it will grow within the realm of pharmaceuticals.
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.